Sleep: Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors

Science Translational Medicine

Volumn 4, Issue 161, 2012, Pages

  Rye, David B ^a   Bliwise, Donald L ^a   Parker, Kathy ^b   Trotti, Lynn Marie ^a   Saini, Prabhjyot ^a   Fairley, Jacqueline ^a   Freeman, Amanda ^a   Garcia, Paul S ^a,c   Owens, Michael J ^a   Ritchie, James C ^a   Jenkins, Andrew ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; FLUMAZENIL; OREXIN; PLACEBO; SODIUM CHLORIDE; CHLORIDE CHANNEL;

ADULT; ALERTNESS; ARTICLE; BODY MASS; CATAPLEXY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE DURATION; DRUG MEGADOSE; EMBRYO; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; HUMAN CELL; HYPERSOMNIA; HYPNOSIS; LOADING DRUG DOSE; MALE; NARCOLEPSY; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STABILITY; REM SLEEP; REPRODUCIBILITY; SEDATION; SIGNAL TRANSDUCTION; SOMNOLENCE; TASK PERFORMANCE; AROUSAL; BEHAVIOR; CELL STRAIN HEK293; CEREBROSPINAL FLUID; CLINICAL TRIAL; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY;

ADULT; AROUSAL; BEHAVIOR; CHLORIDE CHANNELS; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; FLUMAZENIL; HEK293 CELLS; HUMANS; MALE; RECEPTORS, GABA-A; REPRODUCIBILITY OF RESULTS;

EID: 84869745828     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004685     Document Type: Article

References (97)

1. E. Mignot, S. Taheri, S. Nishino, Sleeping with the hypothalamus: Emerging therapeutic targets for sleep disorders. Nat. Neurosci. 5 (Suppl.), 1071-1075 (2002).
2. C. B. Saper, T. E. Scammell, J. Lu, Hypothalamic regulation of sleep and circadian rhythms. Nature 437, 1257-1263 (2005).
3. E. N. Brown, R. Lydic, N. D. Schiff, General anesthesia, sleep, and coma. N. Engl. J. Med. 363, 2638-2650 (2010).
4. A receptors in the physiology and pharmacology of sleep. Eur. J. Neurosci. 29, 1779-1794 (2009).
5. A receptor opening frequency. Curr. Neuropharmacol. 8, 10-17 (2010).
6. N. P. Franks, A. Y. Zecharia, Sleep and general anesthesia. Can. J. Anaesth. 58, 139-148 (2011).
7. E. Costa, A. Guidotti, Recent studies on the mechanism whereby benzodiazepines facilitate GABA-ergic transmission. Adv. Exp. Med. Biol. 123, 371-378 (1979).
8. S. E. File, S. Pellow, Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788. Psychopharmacology 88, 1-11 (1986).
9. S. Ahboucha, R. F. Butterworth, Role of endogenous benzodiazepine ligands and their GABA-A-associated receptors in hepatic encephalopathy. Metab. Brain Dis. 20, 425-437 (2005).
10. P. Lavie, RO 15-1788 decreases hypnotic effects of sleep deprivation. Life Sci. 41, 227-233 (1987).
11. P. Lavie, Intrinsic effects of the benzodiazepine receptor antagonist RO 15-1788 in sleepy and alert subjects. Int. J. Neurosci. 46, 131-137 (1989).
12. E. Seifritz, U. Hemmeter, L. Trachsel, C. J. Lauer, M. Hatzinger, H. M. Emrich, F. Holsboer, E. Holsboer-Trachsler, Effects of flumazenil on recovery sleep and hormonal secretion after sleep deprivation in male controls. Psychopharmacology 120, 449-456 (1995).
13. P. Cortelli, R. Avallone, M. Baraldi, M. L. Zeneroli, J. Mandrioli, L. Corsi, R. Riva, P. Tinuper, E. Lugaresi, A. Baruzzi, P. Montagna, Endozepines in recurrent stupor. Sleep Med. Rev. 9, 477-487 (2005).
14. J. Hardman, L. Limbird, A. Gilman, Goodman & Gilman's: The Pharmacological Basis of Therapeutics (McGraw-Hill, New York, ed. 10, 2001).
15. E. Costa, A. Guidotti, Diazepam binding inhibitor (DBI): A peptide with multiple biological actions. Life Sci. 49, 325-344 (1991).
16. R. A. Lerner, A hypothesis about the endogenous analogue of general anesthesia. Proc. Natl. Acad. Sci. U.S.A. 94, 13375-13377 (1997).
17. P. Sand, D. Kavvadias, D. Feineis, P. Riederer, P. Schreier, M. Kleinschnitz, F. C. Czygan, A. Abou-Mandour, G. Bringmann, H. Beckmann, Naturally occurring benzodiazepines: Current status of research and clinical implications. Eur. Arch. Psychiatry Clin. Neurosci. 250, 194-202 (2000).
18. W. Gowers, The Border-Land of Epilepsy. Faints, Vagal Attacks, Vertigo, Migraine, Sleep Symptoms, and Their Treatment (P. Blakiston's Son & Co., Philadelphia, 1903).
19. S. Wilson, The narcolepsies. Brain 51, 63-109 (1928).
20. B. Roth, S. Nevsimalova, A. Rechtschaffen, Hypersomnia with "sleep drunkenness". Arch. Gen. Psychiatry 26, 456-462 (1972).
21. B. Roth, Narcolepsy and Hypersomnia (Karger, Basel, 1980).
22. T. I. Morgenthaler, V. K. Kapur, T. Brown, T. J. Swick, C. Alessi, R. N. Aurora, B. Boehlecke, A. L. Chesson Jr., L. Friedman, R. Maganti, J. Owens, J. Pancer, R. Zak; Standards of Practice Committee of the American Academy of Sleep Medicine, Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 30, 1705-1711 (2007).
23. K. N. Anderson, S. Pilsworth, L. D. Sharples, I. E. Smith, J. M. Shneerson, Idiopathic hypersomnia: A study of 77 cases. Sleep 30, 1274-1281 (2007).
24. V. Bayon, D. Léger, P. Philip, Socio-professional handicap and accidental risk in patients with hypersomnias of central origin. Sleep Med. Rev. 13, 421-426 (2009).
25. S. Lavault, Y. Dauvilliers, X. Drouot, S. Leu-Semenescu, J. L. Golmard, M. Lecendreux, P. Franco, I. Arnulf, Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med. 12, 550-556 (2011).
26. American Academy of Sleep Medicine, International Classification of Sleep Disorders: Diagnostic and Coding Manual (ICSD-2) (American Academy of Sleep Medicine, Westchester, ed. 2, 2005).
27. M. Carskadon, in Principles and Practice of Sleep Medicine, M. Kryger, T. Roth, and W. Dement, Eds. (WB Saunders Company, Philadelphia, PA, 1994), pp. 962-966.
28. J. Dorrian, N. L. Rogers, D. F. Dinges, in Sleep Deprivation: Clinical Issues, Pharmacology, and Sleep Loss Effects, C. A. Kushida, Ed. (Marcel Dekker Inc., New York, 2005), pp. 39-70.
29. H. P. Van Dongen, G. Maislin, J. M. Mullington, D. F. Dinges, The cumulative cost of additional wakefulness: Dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 26, 117-126 (2003).
30. C. M. Jung, J. M. Ronda, C. A. Czeisler, K. P. Wright Jr., Comparison of sustained attention assessed by auditory and visual psychomotor vigilance tasks prior to and during sleep deprivation. J. Sleep Res. 20, 348-355 (2011).
31. A receptors: Subtypes provide diversity of function and pharmacology. Neuropharmacology 56, 141-148 (2009).
32. A receptors in embryonic mouse neurons. Anesthesiology 89, 1444-1454 (1998).
33. P. S. Glass, M. Bloom, L. Kearse, C. Rosow, P. Sebel, P. Manberg, Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Anesthesiology 86, 836-847 (1997).
34. U. Rudolph, F. Crestani, H. Möhler, J. Barr, T. Delory, J. Lameh, M. Davies, in Anesthetic Pharmacology: Physiologic Principles and Clinical Practice. A Companion to Miller's Anesthesia, A. Evers, M. Maze, Eds. (Churchill Livingstone, Philadelphia, 2004), pp. 417-434.
35. J. G. Whitwam, R. Amrein, Pharmacology of flumazenil. Acta Anaesthesiol. Scand. Suppl. 108, 3-14 (1995).
36. M. Billiard, in Sleepiness - Causes, Consequence, and Treatment, M. Thorpy, M. Billiard, Eds. (Cambridge Univ. Press, New York, 2011), pp. 126-135.
37. R. Khatami, in Narcolepsy - Pathophysiology, Diagnosis and Treatment, C. R. Baumann, C. L. Bassetti, T. E. Scammell, Eds. (Springer, New York, 2011), pp. 357-366.
38. A. A. Borbély, I. Tobler, Endogenous sleep-promoting substances and sleep regulation. Physiol. Rev. 69, 605-670 (1989).
39. J. M. Krueger, J. Fang, M. K. Hansen, J. Zhang, F. Obál Jr., Humoral regulation of sleep. News Physiol. Sci. 13, 189-194 (1998).
40. V. M. Kovalzon, T. V. Strekalova, Delta sleep-inducing peptide (DSIP): A still unresolved riddle. J. Neurochem. 97, 303-309 (2006).
41. M. R. Witt, M. Nielsen, Characterization of the influence of unsaturated free fatty acids on brain GABA/benzodiazepine receptor binding in vitro. J. Neurochem. 62, 1432-1439 (1994).
42. Areceptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis-9,10-octadecenoamide (cOA). Br. J. Pharmacol. 124, 873-882 (1998).
43. C. S. Yost, A. J. Hampson, D. Leonoudakis, D. D. Koblin, L. M. Bornheim, A. T. Gray, Oleamide potentiates benzodiazepine-sensitive γ-aminobutyric acid receptor activity but does not alter minimum alveolar anesthetic concentration. Anesth. Analg. 86, 1294-1300 (1998).
44. J. D. Rothstein, W. Garland, G. Puia, A. Guidotti, R. J. Weber, E. Costa, Purification and characterization of naturally occurring benzodiazepine receptor ligands in rat and human brain. J. Neurochem. 58, 2102-2115 (1992).
45. E. Lugaresi, P. Montagna, P. Tinuper, G. Plazzi, R. Gallassi, T. C. Wang, S. P. Markey, J. D. Rothstein, Endozepine stupor. Recurring stupor linked to endozepine-4 accumulation. Brain 121, 127-133 (1998).
46. E. Lugaresi, P. Montagna, P. Tinuper, G. Plazzi, R. Gallassi, Suspected covert lorazepam administration misdiagnosed as recurrent endozepine stupor. Brain 121 (Pt. 11), 2201 (1998).
47. R. Granot, S. F. Berkovic, S. Patterson, M. Hopwood, O. H. Drummer, R.Mackenzie, Endozepine stupor: Disease or deception? A critical review. Sleep 27, 1597-1599 (2004).
48. N. Le Novère, J. P. Changeux, The Ligand Gated Ion Channel database: An example of a sequence database in neuroscience. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 1121-1130 (2001).
49. T. Kanbayashi, T. Kodama, H. Kondo, S. Satoh, Y. Inoue, S. Chiba, T. Shimizu, S. Nishino, CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 32, 181-187 (2009).
50. C. Christian, J. Huguenard, in Society for Neuroscience National Meeting (Society for Neuroscience, Chicago, IL, 2009), p. Program No. 241.214.
51. N. Neave, C. Reid, A. B. Scholey, J. M. Thompson, M. Moss, G. Ayre, K. Wesnes, N. M. Girdler, Dose-dependent effects of flumazenil on cognition, mood, and cardio-respiratory physiology in healthy volunteers. Br. Dent. J. 189, 668-674 (2000).
52. N. M. Girdler, K. J. Fairbrother, J. P. Lyne, N. Neave, A. Scholey, N. Hargaden, K. A. Wesnes, J. Engler, N. A. Rotherham, A randomised crossover trial of post-operative cognitive and psychomotor recovery from benzodiazepine sedation: Effects of reversal with flumazenil over a prolonged recovery period. Br. Dent. J. 192, 335-339 (2002).
53. J. M. Le Mellédo, M. Van Driel, N. J. Coupland, P. Lott, G. S. Jhangri, Response to flumazenil in women with premenstrual dysphoric disorder. Am. J. Psychiatry 157, 821-823 (2000).
54. E. C. Bell, G. B. Baker, C. Poag, F. Bellavance, J. Khudabux, J. M. Le Mellédo, Response to flumazenil in the late luteal phase and follicular phase of the menstrual cycle in healthy control females. Psychopharmacology 172, 248-254 (2004).
55. N. Wesensten, T. Balkin, G. Balenky, Is the benzodiazepine antagonist flumazenil intrinsically alerting? Sleep Res. 25, 74 (1996).
56. P. Tinuper, P. Montagna, P. Cortelli, P. Avoni, A. Lugaresi, P. Schoch, E. P. Bonetti, R. Gallassi, E. Sforza, E. Lugaresi, Idiopathic recurring stupor: A case with possible involvement of the gamma-aminobutyric acid (GABA)ergic system. Ann. Neurol. 31, 503-506 (1992).
57. M. L. Steyn-Ross, D. A. Steyn-Ross, J. W. Sleigh, Modelling general anaesthesia as a first-order phase transition in the cortex. Prog. Biophys. Mol. Biol. 85, 369-385 (2004).
58. N. D. Schiff, Recovery of consciousness after brain injury: A mesocircuit hypothesis. Trends Neurosci. 33, 1-9 (2010).
59. M. Basner, D. F. Dinges, Maximizing sensitivity of the psychomotor vigilance test (PVT) to sleep loss. Sleep 34, 581-591 (2011).
60. E. J. Silva, W. Wang, J. M. Ronda, J. K. Wyatt, J. F. Duffy, Circadian and wake-dependent influences on subjective sleepiness, cognitive throughput, and reaction time performance in older and young adults. Sleep 33, 481-490 (2010).
61. C. A. Czeisler, J. K. Walsh, T. Roth, R. J. Hughes, K. P.Wright, L. Kingsbury, S. Arora, J. R. Schwartz, G. E. Niebler, D. F. Dinges; U.S. Modafinil in Shift Work Sleep Disorder Study Group, Modafinil for excessive sleepiness associated with shift-work sleep disorder. N. Engl. J. Med. 353, 476-486 (2005).
62. C. Vernet, I. Arnulf, Narcolepsy with long sleep time: A specific entity? Sleep 32, 1229-1235 (2009).
63. C. Vernet, I. Arnulf, Idiopathic hypersomnia with and without long sleep time: A controlled series of 75 patients. Sleep 32, 753-759 (2009).
64. T. Miyagawa, M. Honda, M. Kawashima, M. Shimada, S. Tanaka, Y. Honda, K. Tokunaga, Polymorphism located between CPT1B and CHKB, and HLA-DRB1*1501- DQB1*0602 haplotype confer susceptibility to CNS hypersomnias (essential hypersomnia). PLoS One 4, e5394 (2009).
65. E. Florey, GABA: History and perspectives. Can. J. Physiol. Pharmacol. 69, 1049-1056 (1991).
66. D. L. Bliwise, Is the measurement of sleepiness the holy grail of sleep medicine? Am. J. Respir. Crit. Care Med. 163, 1517-1519 (2001).
67. E. Mignot, Excessive daytime sleepiness: Population and etiology versus nosology. Sleep Med. Rev. 12, 87-94 (2008).
68. M. Broderick, C. Guilleminault, in Sleepiness. Causes, Consequences, and Treatment, M. Thorpy, M. Billiard, Eds. (Cambridge Univ. Press, Cambridge, 2011), p. 475.
69. A receptor channel pharmacology. Curr. Pharm. Des. 11, 1867-1885 (2005).
70. M. W. Johns, A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 14, 540-545 (1991).
71. D. A. Cohen, W. Wang, J. K. Wyatt, R. E. Kronauer, D. J. Dijk, C. A. Czeisler, E. B. Klerman, Uncovering residual effects of chronic sleep loss on human performance. Sci. Transl. Med. 2, 14ra3 (2010).
72. N. J. Wesensten, W. D. Killgore, T. J. Balkin, Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J. Sleep Res. 14, 255-266 (2005).
73. D. B. Rye, B. Dihenia, J. D. Weissman, C. M. Epstein, D. L. Bliwise, Presentation of narcolepsy after 40. Neurology 50, 459-465 (1998).
74. S. Nishino, T. Kanbayashi, Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med. Rev. 9, 269-310 (2005).
75. M. de Vries, T. Klein, C. Hofland, G. Flik, E. Dremencov, T. Cremers, in Society for Neuroscience National Meeting (Society for Neuroscience, San Diego, CA, 2010), p. Program No. 514.519.
76. C. Vianey-Saban, N. Guffon, F. Delolne, P. Guibaud, M. Mathieu, P. Divry, Diagnosis of inborn errors of metabolism by acylcarnitine profiling in blood using tandem mass spectrometry. J. Inherit. Metab. Dis. 20, 411-414 (1997).
77. C. A. Chen, H. Okayama, Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 6, 632-638 (1988).
78. A receptor. J. Biol. Chem. 285, 7281-7287 (2010).
79. O. P. Hamill, A. Marty, E. Neher, B. Sakmann, F. J. Sigworth, Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 391, 85-100 (1981).
80. H. A. Wieland, H. Lüddens, P. H. Seeburg, A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J. Biol. Chem. 267, 1426-1429 (1992).
81. C. Kleingoor, H. A. Wieland, E. R. Korpi, P. H. Seeburg, H. Kettenmann, Current potentiation by diazepam but not GABA sensitivity is determined by a single histidine residue. NeuroReport 4, 187-190 (1993).
82. E. Hoddes, V. Zarcone, H. Smythe, R. Phillips, W. C. Dement, Quantification of sleepiness: A new approach. Psychophysiology 10, 431-436 (1973).
83. R. Slocum, J. Cummings, in Techniques in Diagnostic Human Biochemical Genetics, F. Hommes, Ed. (Wiley-Liss, New York, 1991), pp. 87-126.
84. K. E. Moeller, K. C. Lee, J. C. Kissack, Urine drug screening: Practical guide for clinicians. Mayo Clin. Proc. 83, 66-76 (2008).
85. C. Chen, H. Okayama, High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2745-2752 (1987).
86. M. J. Owens, W. N. Morgan, S. J. Plott, C. B. Nemeroff, Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283, 1305-1322 (1997).
87. T. E. Weaver, A. M. Laizner, L. K. Evans, G. Maislin, D. K. Chugh, K. Lyon, P. L. Smith, A. R. Schwartz, S. Redline, A. I. Pack, D. F. Dinges, An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 20, 835-843 (1997).
88. C. A. McHorney, J. E. Ware Jr., A. E. Raczek, The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31, 247-263 (1993).
89. A. T. Beck, R. W. Beck, Screening depressed patients in family practice. A rapid technic. Postgrad. Med. 52, 81-85 (1972).
90. L. B. Krupp, N. G. LaRocca, J. Muir-Nash, A. D. Steinberg, The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46, 1121-1123 (1989).
91. E. M. Smets, B. Garssen, B. Bonke, J. C. De Haes, The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39, 315-325 (1995).
92. J. Fairley, A. N. Johnson, G. Georgoulas, G. Vachtsevanos, Automated polysomnogram artifact compensation using the generalized singular value decomposition algorithm. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2010, 5097-5100 (2010).
93. H. Bokil, K. Purpura, J. M. Schoffelen, D. Thomson, P. Mitra, Comparing spectra and coherences for groups of unequal size. J. Neurosci. Methods 159, 337-345 (2007).
94. P. Mitra, H. Bokil, Observed Brain Dynamics (Oxford Univ. Press, Oxford, 2008).
95. A. M. Goldfine, J. D. Victor, M. M. Conte, J. C. Bardin, N. D. Schiff, Determination of awareness in patients with severe brain injury using EEG power spectral analysis. Clin. Neurophysiol. 122, 2157-2168 (2011).
96. N. V. Manyam, L. Katz, T. A. Hare, J. C. Gerber III, M. H. Grossman, Levels of γ-aminobutyric acid in cerebrospinal fluid in various neurologic disorders. Arch. Neurol. 37, 352-355 (1980).
97. E. Freye, A. Fournell, Postoperative reversal of loss of vigilance following midazolam with the use of the antagonist flumazenil (Ro 15-1788). A comparative study with a placebo and the use of EEG-power spectra. Anaesthesist 37, 162-166 (1988).